These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 22967104

  • 1. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
    Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Jeong ID, Bang SJ, Lee SH, Kim SR, Park NH.
    J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
    [Abstract] [Full Text] [Related]

  • 2. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment.
    Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.
    Am J Gastroenterol; 2011 Oct; 106(10):1766-73. PubMed ID: 21826112
    [Abstract] [Full Text] [Related]

  • 3. Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg-positive chronic hepatitis B.
    Kwon JH, Jang JW, Lee S, Lee J, Chung KW, Lee YS, Choi JY.
    J Viral Hepat; 2012 Feb; 19(2):e41-7. PubMed ID: 22239525
    [Abstract] [Full Text] [Related]

  • 4. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
    Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, Janssen HL.
    J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
    [Abstract] [Full Text] [Related]

  • 5. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
    Lee MH, Lee DM, Kim SS, Cheong JY, Cho SW.
    J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
    [Abstract] [Full Text] [Related]

  • 6. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R.
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [Abstract] [Full Text] [Related]

  • 7. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
    Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim DY, Hwang SG, Rim KS, Chon CY, Han KH, Park JY.
    Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
    [Abstract] [Full Text] [Related]

  • 8. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL.
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1326-35. PubMed ID: 22506552
    [Abstract] [Full Text] [Related]

  • 9. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
    Ning Q, Han M, Sun Y, Jiang J, Tan D, Hou J, Tang H, Sheng J, Zhao M.
    J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
    [Abstract] [Full Text] [Related]

  • 10. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection.
    Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM.
    Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1984-92.e1. PubMed ID: 26073492
    [Abstract] [Full Text] [Related]

  • 11. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
    Yuen MF, Seto WK, Fung J, Wong DK, Yuen JC, Lai CL.
    Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
    [Abstract] [Full Text] [Related]

  • 12. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U.
    Hepatology; 2010 Feb; 51(2):422-30. PubMed ID: 20049753
    [Abstract] [Full Text] [Related]

  • 13. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 14. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
    Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S.
    J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
    [Abstract] [Full Text] [Related]

  • 15. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, Su TT, Zhou HY, Xu W, Wang XD, Dai YP, Gan JH.
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [Abstract] [Full Text] [Related]

  • 16. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG, Chang TT, Lai CL, de Man RA, Gadano A, Llamoso C, Tang H.
    Antivir Ther; 2013 Feb; 18(5):691-8. PubMed ID: 23510982
    [Abstract] [Full Text] [Related]

  • 17. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R, Cinar K, Seven G, Bozkus Y, Elhan A, Bozdayi M, Yurdaydin C, Bahar K.
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [Abstract] [Full Text] [Related]

  • 18. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy.
    Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF.
    Hepatology; 2013 Sep; 58(3):923-31. PubMed ID: 23468172
    [Abstract] [Full Text] [Related]

  • 19. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.
    Tseng TC, Liu CJ, Su TH, Wang CC, Chen CL, Chen PJ, Chen DS, Kao JH.
    Gastroenterology; 2011 Aug; 141(2):517-25, 525.e1-2. PubMed ID: 21672542
    [Abstract] [Full Text] [Related]

  • 20. Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.
    Chen J, Wang Z, Zhou B, Wang Y, Hou J.
    Antivir Ther; 2012 Aug; 17(1):71-9. PubMed ID: 22267471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.